Introducing Capital Insights – Money Talks with the Investor Community
By Olesia Karvetskaia
Why has the fixed-dose pill survived for nearly two centuries? In the first episode of Capital Insights, our new podcast, OnDosis CEO Martin Olovsson explains how precision dosing could become pharma's biggest untapped opportunity, and what it takes to cross the Atlantic. Read the article, and listen Capital Insights on Spotify.
Executive Ventures isn't the only launch we're celebrating this autumn. We're also proud to introduce Capital Insights, a brand-new podcast shared by Ventures Accelerated and its sister company. Tune in on Spotify, or catch the video snippets on LinkedIn.
Like our written platform, Insights Accelerated, these money talks are hosted by representatives from across the capital stack. They explore the themes that matter most to anyone brave enough to embark on a life science venture: strategy, financing, partnerships, market access, commercialization and global expansion. We don't shy away from the pressing pain points, and we aim to show venture life as it really is.
Each episode brings together one of our own accelerators, an investor and a guest. Guests are founders, executives and industry experts chosen for how honestly they share the challenges they've overcome.
Every topic also has a built-in duality. We pair each guest with their opposite, so the same challenge is seen from two sides. Take crossing the Atlantic.
Episode 1: Rethinking the Dose, with Martin Olovsson, OnDosis
In our first episode, you'll hear from a European company taking the leap into the US market. We sit down with Martin Olovsson, co-founder and CEO of OnDosis, the Gothenburg-based health tech company reinventing oral drug dosing. OnDosis develops drug-device combinations that deliver precise, individualized doses of existing small-molecule medicines. The goal is to help patients reach their lowest effective dose faster.
Martin explains why the fixed-dose pill has lasted for nearly two centuries even though it doesn't reflect individual biology. He also argues that precision dosing could be one of pharma's biggest untapped opportunities. We discuss:
- Crossing the Atlantic: OnDosis's path to a planned 2028 US launch, starting with its ADHD program. Martin explains why a Swedish company needs a real US foothold to be credible with investors, partners and the FDA.
- The real cost of getting the dose wrong: Poor titration leads many ADHD patients to stop treatment. Better dosing could change those outcomes.
- Fitting between MedTech and biotech: How OnDosis pitches investors a MedTech risk profile with pharmaceutical upside.
- Beyond ADHD: Applications in peanut allergy immunotherapy, hypothyroidism, epilepsy, Parkinson's disease and more.
- Advice for European founders: Validating the commercial case early with physicians, payers and patients is just as critical as the science.
Listen to the full first episode on Spotify